Genmab A/S has raised DKK 998 million (€134 million) following the pricing of a previously-announced private share placement to support development of its therapeutic antibody portfolio. The company announced the results on 24 January.
IP Group Plc, which invests in intellectual property generated by universities primarily in the UK, has decided to raise new capital with a share issue. Funds from the issue will enable the company to expand its portfolio of life science investments.
Seventure Partners, an indirect subsidiary of the French financial conglomerate, Natixis SA, has launched a new fund called Health for Life Capital that will invest in companies focused on nutrition and the science relating to the human microbiome.
JLL/Delta Dutch Newco BV, a company set up to combine the assets of Canada’s Patheon Inc and the pharmaceutical division of Royal DSM of the Netherlands, is raising $500 million with a private placement of eight-year notes in New York.
Venture capital-backed 4-Antibody AG of Switzerland is to be acquired by Agenus Inc of the US in a deal intended to exploit the Swiss company’s technology for producing antibodies that target checkpoint molecules, key regulators of the immune system.
Alkermes Plc is raising $250 million from a placement of its shares with the Invesco Perpetual Income Fund and the Invesco Perpetual High Income Fund. The placement comes three months after the company’s product for depression received ‘fast-track’ designation from the FDA.
Sanofi SA will significantly increase its exposure to the RNAi class of medicines under a plan to take a 12% stake in Alnylam Pharmaceuticals Inc of Cambridge, Massachusetts. The equity deal, valued at $700 million, is linked to rights to Alnylam’s portfolio of rare-disease medicines.
The Netherlands-based holding company, Qiagen NV, has broadened its strategic partnership with Exosome Diagnostics Inc of the US in order to develop blood-based molecular diagnostics for certain cancer indications.
Immunocore Ltd of Oxford, UK has secured its third partnership with a major pharmaceutical company relating to the exploitation of its recombinant T-cell receptor technology platform – this time with MedImmune, the biologics unit of AstraZeneca Plc.
Santaris Pharma A/S of Denmark has entered into a strategic alliance with Roche to discover and develop RNA-targeted medicines using locked nucleic acid technology which has been developed by Santaris.